| Sara Lynn Hornbein, MD | |
|
2741 Debarr Rd, Suite C-308, Anchorage, AK 99508-2953 | |
| (907) 272-3366 | |
| (907) 272-0269 |
| Full Name | Sara Lynn Hornbein |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 2741 Debarr Rd, Anchorage, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578787800 | NPI | - | NPPES |
| MD2515 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | AA2515 (Alaska) | Primary |
| Entity Name | Mat - Su Health Services Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184725210 PECOS PAC ID: 2567354533 Enrollment ID: O20040325000998 |
News Archive
An ophthalmology research team at the University of Wisconsin-Madison took part in a nationwide clinical trial comparing treatments for a form of diabetic eye disease. The study found that three commonly used drugs perform much the same for those with mild vision problems, but one medication performed better for those with more serious vision loss.
The number of tuberculosis patients diagnosed and treated under DOTS, the internationally recommended strategy for TB control, is now rising much faster than at any time since DOTS expansion began in 1995, according to a new report by the World Health Organization (WHO). Indeed, the past two years have witnessed accelerated growth in the implementation of DOTS programmes worldwide.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD).
Women who begin menopause before age 46 or after 55 have an increased risk of developing type 2 diabetes, according to a study of more than 124,000 women enrolled in the Women's Health Initiative, a large national trial aimed at preventing disease in postmenopausal women.
Now, with your own personal Breast Angel in hand, through the science of trans-dermal illumination, you are going to be able to actually see inside your breasts. With routine monthly use, you will learn to discern exactly what your normal internal physiological appearance is, and more importantly, what is not. Your monthly breast self-exams no longer have to be a dreaded procedure nor a confusing one.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sara Lynn Hornbein, MD 2741 Debarr Rd, Suite C-308, Anchorage, AK 99508-2953 Ph: (907) 272-3366 | Sara Lynn Hornbein, MD 2741 Debarr Rd, Suite C-308, Anchorage, AK 99508-2953 Ph: (907) 272-3366 |
News Archive
An ophthalmology research team at the University of Wisconsin-Madison took part in a nationwide clinical trial comparing treatments for a form of diabetic eye disease. The study found that three commonly used drugs perform much the same for those with mild vision problems, but one medication performed better for those with more serious vision loss.
The number of tuberculosis patients diagnosed and treated under DOTS, the internationally recommended strategy for TB control, is now rising much faster than at any time since DOTS expansion began in 1995, according to a new report by the World Health Organization (WHO). Indeed, the past two years have witnessed accelerated growth in the implementation of DOTS programmes worldwide.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD).
Women who begin menopause before age 46 or after 55 have an increased risk of developing type 2 diabetes, according to a study of more than 124,000 women enrolled in the Women's Health Initiative, a large national trial aimed at preventing disease in postmenopausal women.
Now, with your own personal Breast Angel in hand, through the science of trans-dermal illumination, you are going to be able to actually see inside your breasts. With routine monthly use, you will learn to discern exactly what your normal internal physiological appearance is, and more importantly, what is not. Your monthly breast self-exams no longer have to be a dreaded procedure nor a confusing one.
› Verified 5 days ago
Candace L Clawson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-729-1624 Fax: 907-729-1634 | |
Dr. William Murray Buttner, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 E 36th Ave, Anchorage, AK 99508 Phone: 907-562-9229 Fax: 907-561-4806 | |
Robert L Mcalister, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 E 36th Ave, Anchorage, AK 99508 Phone: 907-562-2992 | |
Shane W Cummings, M D Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1310 E Dimond Blvd, Suite 1, Anchorage, AK 99515 Phone: 907-344-2400 Fax: 907-344-2404 | |
Jeremy D Wood, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 910 Compassion Cir, Anchorage, AK 99504 Phone: 907-212-9200 Fax: 907-212-9283 | |
Kelton Hillard Oliver, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 12302 Woodward Dr, Anchorage, AK 99516 Phone: 907-580-0002 | |
Ryan T. Mcwilliams, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4320 Diplomacy Dr, Suite 1191, Anchorage, AK 99508 Phone: 907-729-6321 |